MeadWestvaco System Chosen for HIV-Prevention Trials
Global packaging company has received a grant from The Bill & Melinda Gates Foundation to improve adherence and accuracy during PrEP trials
MeadWestvaco (MWV), a provider of packaging and packaging solutions, has received a grant to provide its Medication Event Monitoring System (MEMS™) to The Bill & Melinda Gates Foundation’s new demonstration projects on pre-exposure prophylaxis (PrEP) medications to help prevent the spread of HIV/AIDS in sub-Saharan Africa and India. The four studies launched in October 2014.
These medications are given to high-risk but HIV-negative people, and have been shown to prevent transmission of the virus when people are adherent to their medication program. MWV’s MEMS System utilizes its MEMSCap™ smart electronic medication packaging. The system tracks each time the medication bottle is opened, a proven corollary for measuring when a pill is taken. These data are wirelessly transferred to MWV Healthcare’s MedAmigo™ platform, a secure, web-based program for data analysis and modeling.
During the foundation’s trials, MWV’s scientific staff will analyze adherence data and provide trial coordinators with real-time feedback about each participant’s adherence. When provided to participants, this real-time feedback at the point of care has been shown to be the most effective adherence intervention available. In recent draft guidance, the FDA has recommended using smart medication packaging to measure and enhance adherence in clinical trials.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
